



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Goulmy et al.

Serial No.: 10/623,176

Filed: July 18, 2003

For: HA-1 EPITOPES AND USES  
THEREOF

Confirmation No.: 4726

Examiner: M. Szperka

Group Art Unit: 1644

Attorney Docket No.: 2183-6047US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 24, 2005  
Date

  
Signature

Aubry Blackburn  
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of U.S. patents are not being submitted pursuant to M.P.E.P. 609 III A(2). Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2)

Pursuant to 37 C.F.R. § 1.98(d), a copy of any patent, publication or other information listed in the Information Disclosure Statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior

Serial No.: 10/623,176

application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. § 120.

Accordingly, no copy of information marked with a pound sign (#) is enclosed because it was previously cited or submitted to the patent office in a prior application which is properly identified above, and is relied upon for an earlier filing date. The references are as follows:

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,770,201	06-23-1998	Goulmy et al.
US - 6,521,598 B1	02-18-2003	Goulmy et al.
US - 6,830,883 B1	12-14-2004	Goulmy
US - 6,878,375 B1	04-12-2005	Goulmy et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
EP 0 965 648 A1	12-22-1999	Rijksuniversiteit Leiden
WO 97/04798	02-13-1997	University of Virginia Patent Foundation
WO 99/05173	02-04-1999	Rijksuniversiteit te Leiden
WO 99/05174	02-04-1999	Rijksuniversiteit te Leiden
WO 99/05313	02-04-1999	Rijksuniversiteit Leiden
WO 01/94940 A1	12-13-2001	Stichting Sanquin Bloedvoorziening
WO 03/047606 A2	06-12-2003	Academisch Ziekenhuis Leiden
#WO 97/05168	02-13-1997	Goulmy
#WO 97/05169	02-13-1997	Goulmy

Other Documents

#GOULMY et al., The Role of Human Minor Histocompatibility Antigens in Graft Failure: a Mini-review, Eye, 1995, pp. 180-84, Vol. 9, Royal College of Ophthalmologists.

#DEN HAAN et al., Conservation of Minor Histocompatibility Antigens Between Human and Non-human primates, Eur. J. Immunol., 1996, pp. 2680-85, Vol. 26.

#DEN HAAN et al., Identification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility Antigen, Science, June 9, 1995, pp. 1476-80, Vol. 268.

#DEN HAAN et al., The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism, Science, February 13, 1998, pp. 1054-57, Vol. 279,

#VAN DER HARST et al., Recognition of Minor Histocompatibility Antigens on Lymphocytic and Myeloid Leukemic Cells by Cytotoxic T-Cell Clones, 1994, pp. 1060-66, The American Society of Hematology.

#COLMAN et al., Effects of amino acid sequence changes on antibody-antigen interaction, 1994, A structural view of immune recognition by antibodies, pp. 33-36.

#ABBAS et al., Cellular and Molecular Immunology, 1991, Antigen Presentation and T cell Recognition, p. 130.

#NAGASE et al., DNA Res. 1996, pp. 321-29, Vol. 3.

#PAUL et al., Fundamental Immunology, 2nd Edition, Raven Press, 1989, pp.; 987-88.

#STRYER et al., Biochemistry, 1998, pp. 31-33, W.H. Freeman and Company, New York.

#NGO et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 492-95.

#TISCH et al., Proc. Natl. Acad. Sci., 1994, pp. 437-38, Vol. 91, USA.

#ANDERTON et al., Immunology, 2001, pp. 367-76, Vol. 104.

#PEAKMAN et al., Immunology, 2001, pp. 351-66, Vol. 104.

FALLER et al., "Human T-Cell Leukemia Virus Type I Infection of CD4+ or CD8+ Cytotoxic T-Cell Clones Results in Immortalization with Retention of Antigen Specificity," J. of Virology, August 1988, pp. 2942-2950, vol. 62, no. 8.

**Serial No.: 10/623,176**

BAKKER et al., "Generation of Antimelanoma Cytotoxic T Lymphocytes from Healthy Donors after Presentation of Melanoma-associated Antigen-derived Epitopes by Dendritic Cell in Vitro," Cancer Research, 15 November 1995, pp. 5330-5334, vol. 55.

GOULMY, "Minor Histocompatibility Antigens: From T Cell Recognition to Peptide Identification," Human Immunology, April 1997, pp. 8-14, vol. 54.

MIYAZAKI et al., "Potential limitations in using minor histocompatitbilty antigen-specific cytotoxin T cells for targeting solid tumor cells," Clinical Immunology, 2003, pp. 198-201, vol. 107.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/489,760

Filed: January 21, 2000

For: THE HA-1 ANTIGEN, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2183-4285.1US  
Serial No.: 10/791,217  
Filing Date: 3/2/2004  
Title: THE HA-1 ANTIGEN


Attorney Docket No.: 2183-6479US  
Serial No.: 10/861,335  
Filing Date: 6/4/2004  
Title: MINOR HISTOCOMPATIBILITY ANTIGEN HA-1: TARGET ANTIGEN FOR IMMUNOTHERAPY OF TUMORS

**Serial No.: 10/623,176**

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: June 13, 2005

ACT/bv

Enclosures: Form PTO/SB/08

Copy of documents cited

Check in the amount of \$180.00

Document in ProLaw



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/623,176
Filing Date	July 18, 2003
First Named Inventor	Goulmy et al.
Group Art Unit	1644
Examiner Name	M. Szperka
Attorney Docket Number	2183-6047US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 5,770,201	06-23-1998	Goulmy et al.	
		US- 6,521,598 B1	02-18-2003	Goulmy et al.	
		US- 6,830,883 B1	12-14-2004	Goulmy	
		US- 6,878,375 B1	04-12-2005	Goulmy et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		EP 0 965 648 A1	12-22-1999	Rijksuniversiteit Leiden		
		WO 97/04798	02-13-1997	University of Virginia Patent Foundation		
		WO 99/05173	02-04-1999	Rijksuniversiteit te Leiden		
		WO 99/05174	02-04-1999	Rijksuniversiteit te Leiden		
		WO 99/05313	02-04-1999	Rijksuniversiteit Leiden		
		WO 01/94940 A1	12-13-2001	Stichting Sanquin Bloedvoorziening		
		WO 03/047606 A2	06-12-2003	Academisch Ziekenhuis Leiden		
		#WO 97/05168	02-13-1997	Goulmy		
		#WO 97/05169	02-13-1997	Goulmy		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

**Complete if Known**

Application Number	10/623,176
Filing Date	July 18, 2003
First Named Inventor	Goulmy et al.
Group Art Unit	1644
Examiner Name	M. Szperka
Attorney Docket Number	2183-6047US

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		#GOULMY et al., The Role of Human Minor Histocompatibility Antigens in Graft Failure: a Mini-review, Eye, 1995, pp. 180-84, Vol. 9, Royal College of Ophthalmologists.	
		#DEN HAAN et al., Conservation of Minor Histocompatibility Antigens Between Human and Non-human primates, Eur. J. Immunol., 1996, pp. 2680-85, Vol. 26.	
		#DEN HAAN et al., Identification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility Antigen, Science, June 9, 1995, pp. 1476-80, Vol. 268.	
		#DEN HAAN et al., The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism, Science, February 13, 1998, pp. 1054-57, Vol. 279,	
		#VAN DER HARST et al., Recognition of Minor Histocompatibility Antigens on Lymphocytic and Myeloid Leukemic Cells by Cytotoxic T-Cell Clones, 1994, pp. 1060-66, The American Society of Hematology.	
		#COLMAN et al., Effects of amino acid sequence changes on antibody-antigen interaction, 1994, A structural view of immune recognition by antibodies, pp. 33-36.	
		#ABBAS et al., Cellular and Molecular Immunology, 1991, Antigen Presentation and T cell Recognition, p. 130.	
		#NAGASE et al., DNA Res. 1996, pp. 321-29, Vol. 3.	
		#PAUL et al., Fundamental Immunology, 2nd Edition, Raven Press, 1989, pp.; 987-88.	
		#STRYER et al., Biochemistry, 1998, pp. 31-33, W.H. Freeman and Company, New York.	
		#NGO et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 492-95.	
		#TISCH et al., Proc. Natl. Acad. Sci., 1994, pp. 437-38, Vol. 91, USA.	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

**Complete if Known**

Application Number	10/623,176
Filing Date	July 18, 2003
First Named Inventor	Goulmy et al.
Group Art Unit	1644
Examiner Name	M. Szperka
Attorney Docket Number	2183-6047US

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		#ANDERTON et al., Immunology, 2001, pp. 367-76, Vol. 104.	
		#PEAKMAN et al., Immunology, 2001, pp. 351-66, Vol. 104.	
		FALLER et al., "Human T-Cell Leukemia Virus Type I Infection of CD4+ or CD8+ Cytotoxic T-Cell Clones Results in Immortalization with Retention of Antigen Specificity," J. of Virology, August 1988, pp. 2942-2950, vol. 62, no. 8.	
		BAKKER et al., "Generation of Antimelanoma Cytotoxic T Lymphocytes from Healthy Donors after Presentation of Melanoma-associated Antigen-derived Epitopes by Dendritic Cell in Vitro," Cancer Research, 15 November 1995, pp. 5330-5334, vol. 55.	
		GOULMY, "Minor Histocompatibility Antigens: From T Cell Recognition to Peptide Identification," Human Immunology, April 1997, pp. 8-14, vol. 54.	
		MIYAZAKI et al., "Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells," Clinical Immunology, 2003, pp. 198-201, vol. 107.	

Examiner  
SignatureDate  
Considered

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/489,760

Filed: January 21, 2000

For: THE HA-1 ANTIGEN, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.